शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
CAMLINFINENSECamlin Fine Sciences Limited· Chemicals & PetrochemicalsHighNeutral
Announced Mon, 10 Nov, 2025 · 15:59 IST

Sales rise 10%, but the company remains loss-making

Pat NegativeEbitda Margin CompressionResults View source PDFExplain this filing

CAMLINFINE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-10.2%Reaction day
₹188.68
prior close
₹186.00
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-0.3%-9.9% vs market
Specialty Chemicals peers, median of 86sector-0.8%-9.4% vs sector

On the reaction day the stock moved 9.9 pts less than Nifty Microcap 250 and 9.4 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-5.9
10m
-3.9
15m
-4.5
30m
-7.5
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-10.2-0.3-9.9-0.8-9.4
Next day
-9.8+0.7-10.5+0.4-10.3
2d
-9.6+0.6-10.2-0.2-9.4
3d
-11.8+0.5-12.2-1.0-10.7
4d
-9.7+1.1-10.8-0.8-8.9
5d
-14.7+0.3-14.9-2.0-12.7
1w
-15.8-0.2-15.6-2.9-12.9
15d
-14.5-2.2-12.2-4.7-9.8
1m
-22.4-4.9-17.4-6.4-16.0
2m
-19.6-7.5-12.1-9.6-9.9
3m
-8.8-4.8-4.1-9.5+0.6
UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 86Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Consolidated sales rose 10.2% year on year to Rs 459.83 crore in the quarter ended September 2025, but the net loss was Rs 14.95 crore versus Rs 116.11 crore; last year's loss included large asset write-down charges. First-half sales rose 10.7% to Rs 883.38 crore, with a Rs 25.63 crore loss and Rs 67.14 crore from operations. The review report had no qualification. The Board also approved 16.23 lakh employee options at Rs 150 each.

Likely market impact

Sales growth and cash from operations help, but continuing losses and lower margins may keep the stock under pressure.